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ABSTRACT 
MENINGOCOCCAL 
B VACCINATION: 
A NOVEL APPROACH 
SIMON ATTARD MONTALTO 
Meningococcal B disease is associated with a mortality of up to 10% and significant morbidity in survivors. Attempts to produ.ce 
an effective vaccine based on established methods over several decades, have succeeded in designing vaccines suitable only for 
local and strain-specific outbreaks. To date, the 4CMenB vaccine is the first preventative measure that is effective on a global 
endemic level and could potentially cover against 80% of isolates that cause this devastating disease. Although costly, this 
vaccine appears to be safe and can be given with other vaccines. Early trials of a 3+ 1 infant schedule have shown encouraging 
levels of seroprotection at 13 months of almost 100% for all four vaccine components. Results from widespread national 
programmes have shown uptake levels for the vaccine in excess of 95% of the target population, and Significant reductions 
in invasive meningococcal B disease by more than 50% of cases within just 10 months of starting the programme. Long 
term surveillance for late adverse events and to determine the duration of protection is ongoing, and countries will need to 
independently establish the cost-benefit and feasibility of a 4CMenB programme. 
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INTRODUCTION 
Although relatively uncommon, invasive meningococcal 
disease (IMD) is one of the most deadly infections affecting 
healthy infants, children and young adults. Out of a total of 
12 circulating capsular groups of Neisseria meningitidis, just 
6 account for over 90% of significant infection 1. In Europe, 
North America and Australasia, most of these cases are due to 
meningococcal capsular group B and, to a lesser extent, group C 
organisms, whereas group A is endemic in Africa (Figure 1)2. 
Silent nasopharyngeal carriage of N. meningitidis can be as 
high as 10% within the adult population during the 'cold and 
flu season, increasing the risk of transmission especially from 
persons in close contact in confined spaces. Although this 
accounts for the 'case clusters' during social events, amongst 
army recruits and university students3, most cases are sporadic 
and the reason why some individuals appear to be more 
susceptible and go on to develop invasive disease is not clearly 
understood. Invasion occurs after a short incubation period of 
an average of 4 days (range 2-10 days) and, in the majority of 
cases, results in meningitis, septicaemia or both. The inherent 
severity of these conditions, combined with a fulminating 
course associated with an immunological cascade with serious 
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complications including disseminated intravascular coagulation, 
shock and cardiovascular collapse, results in an overall case 
fatality rate of around 5-15%4,5. In those who survive, significant 
long term morbidity is present in around 10-20% and includes 
loss of digits and/or limbs, renal failure, blindness, deafness, 
cerebral pa,lsy, cognitive impairment and epilepsy5. 
The rapidity of the infection and alarmingly high mortality 
and morbidity have ensured that meningococcal disease 
retains a high profile within medical circles as well as the 
general public. A Significant amount of effort and resources 
have been directed to treat the acute illness, but also to prevent 
disease in the first place through vaccination. This has been 
very successful for some capsulaI' groups including Men N 
and C , but has been Singularly difficult with regard to Men B 
disease where organism-derived antibody-inducing antigens 
within existing vaccines closely resemble human antigens and 
are, therefore, recognised as 'self' and render these vaccines 
non-immunogenic8. After decades of disappointment with 
early vaccines, a totally novel approach was reqUired and this 
has now been successful in creating a vaccine that generates 
protection against 66-92% of circulating capsular group B N. 
meningitidis strains9• 
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DISCUSSION 
THE BURDEN OF DISEASE 
In 2012, surveillance by the European Centre for Disease 
Prevention and Control (ECDC) confirmed that IMD 
comprised 43% meningitis, 29% septicaemia, 21 % combined 
meningitis and septicaemia and the remaining 7% included 
septic arthritis, pneumonia, conjunctivitis, cervicitis, pericarditis 
and endocarditis lO• This pattern of disease is true for both 
meningococcal Band C, although septicaemia is more common 
with group Y (50% versus 30% meningitis alone and 10% 
combined), whilst both meningitis and septicaemia comprise 
40% of cases for group Wand 45% for group A (versus 25% with 
meningitis and 15% septicaemia alone)l l. 
IMD generally affects infants and, to a ~esser extent, 
preschool-age children, adolescents and young adults. This is true 
both for epidemiCS and during natural background infection. 
For example, during the Men B epidemiC in New Zealand over 
1991-96, the incidence was 1421100,000 in infants and 731100,000 
for preschool children12, whilst the non-epidemic infection rate 
for Men B in Europe over 2014-16 was 10.51100,000 in infants, 
2.5/100,000 for 1-4 year olds, 0.81100,000 for 5-24 year olds and 
0.2-0.3 in older age groups l3. Gender does not appear to be a 
factor, with infection rates being similar for boys and girls. 
A comprehensive epidemiological review of IMD in 
Malta14 has confirmed an overall incidence rate for all types 
of meningococcal disease in 2000-2012 of 1.71100,000, well 
above the European average of 1.1/100,000 for the same time 
period. The individual incidence rate was 0.99 and 0.311'00,000 
for groups Band C, respectively, and the case fatality rate was 
above the European average, particularly with regard to Men 
C with 21 % of cases compared with 11-15% for the rest of 
Europel4. Indeed, these figures would convincingly support the 
case for nationwide, population-based protection against Men 
C disease, particularly since several effective Men C vaccines 
have been widely available for almost two decades15 . In contrast, 
this has not been the case for Men B where effective vaccine 
development has proven to be very difficult. 
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distribution of AWXC meningococcal 
capsular groups 
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EARLY MEN B VACCINES 
Early vaccines against Men C were purely polysaccharide-based and 
were designed to generate immunity against the meningococcal 
capsular polysaccharides. These vaccines were poorly immunogenic 
especially in those under the age of two, and had no effect on nasal 
carriage with waning protection over time16• 
Protein-polysaccharide conjugate vaccines were later 
developed. These were found to be safe and effective, even 
in infants, against Men A, C and in combination e.g. ACWY. 
Further development of these vaccines with, for example, 
alterations in the adjuvant or type of carrier protein used, 
improved the vaccines immunogenicityl7, and these conferred 
effective long term immunity. Consequently, over the past 15 
years or so, many Men Cl ACWY combination vaccines have 
been introduced into routine national schedules with very good 
effect. In the UK, nationwide Men C immunisation commenced 
in November 1999 and has reduced the rates of Men C disease in 
children to almost no cases per yearl8. 
The situation with Men B was different. Unlike other 
meningococcal capsular groups, the Men B organism contains 
polysialic acid within its outer capsule, a compound that also 
forms part of the neural cell adhesion molecule (NCAM) in 
humans. This homophilic binding glycoprotein is expressed on 
several human cells including neurones, glia and skeletal muscle. 
Hence, its introduction within classical protein-polysaccharide 
conjugate vaccines derived from meningococcal B capsulaI' 
components ensures that the vaccine is recognised as a 'self-
antigen' and immune-tolerance guarantees a poor antibody 
response. An alternative approach was to revert to 'whole cell' 
vaccines but Men B strains are widely diverse and, therefore, 
several whole cell vaccines would be required to cover all major 
Men B pathogens. Other vaccines utilising protein anti genic 
components from the outer membrane vesicles (OMV) that are 
shed by the meningococcus during replication were developed. 
However, since the OMVs are strain-specific, these vaccines are 
only effective against meningococcal strains sharing the same 
proteins found in the OMVs. 
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In p'ractice, they proved effective in isolated outbreaks 
involving single strains in Norway in 1990 with 57.2% 
protectionl9, Cuba in 1990 with 83% efficacy2°, and Normandy, 
France in 200321 . In effect, these were tailor-made vaccines for 
isolated outbreaks and an alternative approach was required in 
order to design a vaccine that would offer effective protection for 
global endemic disease. 
A NEW APPROACH TO VACCINATION 
Reverse vaccinology was the phrase coined to describe this 
new approach. Using modern gene sequencing techniques, the 
entire meningococcus genome was determined, and repeatedly 
put through computer programmes to identify gene sequences 
that coded for antigenic proteins that, in turn, resulted in an 
immune response. To be 'eligible' for possible inclusion into 
a vaccine, these genes also had to be common to different 
meningococcal strains. Thousands of candidate genes were 
whittled down to just three major antigenic proteins (Table 1), 
and these were then combined with the OMV protein antigen 
from the strain-specific OMV vaccine developed in New 
Zealand in 1997, to create a new Men B vaccine22• 
Table 1. Components of 4CMenB vaccine 
Component Action 
NadA 
NHBA 
fHbp 
NZPoA 1.4 
Promotes adherence to human epithelial cells 
Binds heparin, prolonging bacterial 
survival in blood 
Binds factor H, allowing bacterial 
survival in blood 
Induces strain specific bactericidal response 
TO-DATE THERE HAVE BEEN NO MAJOR SAFETY 
ISSUES, WITH AROUND 25% OF VACCINEES 
DEVELOPING A FEVER. THIS DOUBLES TO 50% 
IF 4CMENB IS GIVEN IN COMBINATION 
WITH OTHER VACCINES 
EARLY RESULTS OF NEW VACCINE 
The resulting four-component Men B (4CMenB) vaccine was, 
during subsequent clinical trials, found to be safe and highly 
immunogenic against several strains of Men B23. A three dose 
priming course in the first few months (2, 4 and 6 months) 
followed by a booster dose at twelve months was shown to 
produce very high and persistent bactericidal antibody levels 
against all four components at 13 months24 • This vaccine is based 
entirely on subcapsular meningococcal components and can, 
therefore, potentially offer some cross protection against other 
meningococcal serotypes that share these core proteins. Variations 
within Men B strains will account for some differences in immune 
response after vaccination, but a comprehensive review of Men B 
strains by country have predicted adequate cover against 80% of 
all currently circulating isolates (ranging from 66% in Canada to 
91 % in the USA, Figure 2)9. 
To-date there have been no major safety issues, with around 
25% of vaccinees developing a fever. This doubles to 50% if 
4CMenB is given in combination with other vaccines and, for this 
reason, it has been recommended to co-administer paracetamol 
prophylactically together with the vaccine. This reduces the risk of 
fever to 'background' levels whilst also alleviating pain, fussiness 
and other minor adverse events25. Concerns have been raised that 
co-administering paracetamol reduces the immunogenicity of 
4CMenB vaccines. However, although antibody responses to the 
4CMenB vaccines are reduced with paracetamol, titres are still 
maintained well above seroprotective levels26. 
GERMANY 82% NORWAY 85% 
CANADA 66% 
Figure 2. Projected 
cover of meningococcal B 
isolates by 4CMenB 
for 11 countries' 
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UK73% 
AUSTRALIA 76% 
SPAIN 69% 
FRAN CE 85% ITALY 87% 
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FUTURE CONSIDERATIONS FOR 4CMENB 
The difficulty, duration and complexity of developing this 
new vaccine have resulted in a hefty price tag (estimated at 
approximately £100 per dose, for a 3 or 4-dose programme). 
Given that meningococcal B is a rare disease affecting roughly 
1:100,000 and has a varying incidence with fluctuating peaks 
and troughs over several-year cycles, the price for national 
vaccine coverage may be difficult to justify. Furthermore, there 
may be problems introducing yet another multi-dose vaccine 
into busy national immunisation schedules. On the other hand, 
this is offset by. the severity of this disease with 10% mortality 
and 20% significant morbidity, and effectiveness of the vaccine. 
Indeed, the introduction of 4CMenB in Quebec, a highly 
endemic Men B region in Canada in 2013, and to selected 
university students in the US, resulted in no MenB cases and 
no safety issues in vaccinees27. Every country will need to weigh 
all options on an individual basis and, for example, the UK 
have altered their position from "not cost effective" in 2013 to 
"recommended for national coverage" by 2014 and introduced in 
2015. Uptake for the first and second doses in the UK have now 
reached >95% and >90% of the target population, respectively, 
and within 10 months of introducing 4CMenB, the number of 
cases with Men B meningitis and/or septicaemia have halved. 
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Other countries like France have introduced 4cMenB at a local 
level with encouraging preliminary results28• 
Clearly, the results of post-immunisation surveillance from 
all these programmes will be awaited with great interest. Once 
wide coverage is attained and herd immunity established, it may 
well be possible to reduce the number of priming and booster 
doses required, as happened with Men C and Men ACWY 
vaccine programmes29. 
CONCLUSION 
To-date, the 4CMenB vaccine is the first effective 
preventative measure against this devastating disease. Although 
costly, it appears to be safe, and can be given with other vaccines 
although co-administered paracetamol is recommended. 
Long term surveillance to exclude any late adverse events 
and to determine the effectiveness and duration of protection 
is required. Individual countries will need to complete an 
individual country-specific exercise to 'establish the cost-benefit 
and feasibility of a 4CMenB programme. :< 
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